SCHEMBL24812437

SCHEMBL24812437

O=C(O)C1(c2c[nH]c3ccccc23)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.50
MAPT P10636 5/20 0.48
GPR84 Q9NQS5 1/20 0.47
CYP2D6 P10635 1/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A4 P31645 1/20 0.47
SLC6A3 Q01959 1/20 0.47
MGAM O43451 1/20 0.45
GAA P10253 1/20 0.45
SI P14410 1/20 0.45
MGAM2 Q2M2H8 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
TP53 P04637 1/20 0.45
HSD11B1 P28845 1/20 0.45
ALDH1A1 P00352 2/20 0.45
PBRM1 Q86U86 1/20 0.45
ATM Q13315 1/20 0.45
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30050333 1.00 HDAC1 (0.50) HDAC1MAPTGPR84CYP2D6SLC6A2
SCHEMBL24814502 0.85 PBRM1 (0.51) HDAC1MAPTGPR84CYP2D6SLC6A2
SCHEMBL3720163 0.85 ALDH1A1 (0.51) HDAC1MAPTGPR84CYP2D6SLC6A2
SCHEMBL29800970 0.81 NR4A2 (0.51) HDAC1MAPTGPR84SMN1; SMN2TP53
SCHEMBL22864441 0.81 NR4A2 (0.51) HDAC1MAPTGPR84SMN1; SMN2TP53
SCHEMBL25139734 0.81 MAPT (0.47) HDAC1MAPTGPR84SLC6A2SLC6A4
SCHEMBL30390141 0.80 HDAC1 (0.53) HDAC1MAPTGPR84CYP2D6SLC6A2
SCHEMBL3243758 0.78 HDAC1 (0.55) HDAC1MAPTGPR84CYP2D6SLC6A2
SCHEMBL8870589 0.76 CYP2D6 (0.44) HDAC1MAPTGPR84CYP2D6SLC6A2
SCHEMBL8870584 0.76 CYP2D6 (0.44) HDAC1MAPTGPR84CYP2D6SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12053459-B2 CDK2 inhibitors and methods of using the same CEDILLA THERAPEUTICS, INC. (MA) 2024-08-06 US disclosed
EP-4358954-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME Cedilla Therapeutics, Inc. (US) 2024-05-01 EP disclosed
CN-117561058-A CDK2 inhibitors and methods of use thereof 塞迪拉治疗股份有限公司 2024-02-13 CN disclosed
US-20230121337-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. 2023-04-20 US disclosed
US-20230121337-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. 2023-04-20 US disclosed
WO-2022272106-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2022-12-29 WO disclosed
WO-2022272106-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2022-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230121337-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CDK2, CDK20, CDK2AP2 HDAC1 423/4885MAPT 3481/4885GPR84 4585/4885
US-12053459-B2 CDK2 inhibitors and methods of using the same CDK2, CDK20, CDK2AP2 HDAC1 423/4885MAPT 3481/4885GPR84 4585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.